Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells

Vaccine

Volumn 29, Issue 18, 2011, Pages 3465-3475

  Sistigu, A ^a   Bracci, L ^a   Valentini, M ^a   Proietti, E ^a   Bona, R ^a   Negri, D R M ^a   Ciccaglione, A R ^a   Tritarelli, E ^a   Nisini, R ^a   Equestre, M ^a   Costantino, A ^a   Marcantonio, C ^a   Santini, S M ^a   Lapenta, C ^a   Donati, S ^a   Tataseo, P ^b   Miceli, M ^c   Cara, A ^a   Federico, M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ASL Avezzano Sulmona   (Italy)

^c Azienda San Camillo Forlanini   (Italy)

Author keywords

Cross presentation; CTLs; Dendritic cells; Nef; Src tyrosine kinases; VLPs

Indexed keywords

AMINO ACID; GAMMA INTERFERON; NEF PROTEIN; NONSTRUCTURAL PROTEIN 3; PROTEIN E6; PROTEIN E7; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL STRAIN HEK293; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; HEK293 CELLS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA-BINDING PROTEINS; SRC-FAMILY KINASES; VACCINES, VIRUS-LIKE PARTICLE; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79954842506     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.059     Document Type: Article

References (59)

1. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
2. Johnson M.C., Scobie H.M., Ma Y.M., Vogt V.M. Nucleic acid-independent retrovirus assembly can be driven by dimerization. J Virol 2002, 76(22):11177-11185.
3. Young K.R., Ross T.M. Particle-based vaccines for HIV-1 infection. Curr Drug Targets Infect Disord 2003, 3(2):151-169.
4. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307(5947):178-180.
5. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
6. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002, 83(Pt 9):2091-2108.
7. Reading S.A., Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch Virol 2007, 152(6):1047-1059.
8. Wang Z., La R.C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 2006, 35(3):324-331.
9. Gilbert P.A., McFadden G. Poxvirus cancer therapy. Recent Pat Antiinfect Drug Discov 2006, 1(3):309-321.
10. He Y., Munn D., Falo L.D. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines 2007, 6(6):913-924.
11. Liniger M., Zuniga A., Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007, 6(2):255-266.
12. Yang T.C., Millar J.B., Grinshtein N., Bassett J., Finn J., Bramson J.L. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines 2007, 6(3):347-356.
13. Anderson R.J., Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007, 25:2B24-12B.
14. Laddy D.J., Weiner D.B. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006, 25(3-4):99-123.
15. Liu M.A., Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005, 5525-5540.
16. Lowe D.B., Shearer M.H., Kennedy R.C. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem 2006, 98(2):235-242.
17. Peretti S., Schiavoni I., Pugliese K., Federico M. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol Ther 2005, 12(6):1185-1196.
18. Peretti S., Schiavoni I., Pugliese K., Federico M. Selective elimination of HIV-1-infected cells by Env-directed, HIV-1-based virus-like particles. Virology 2006, 345(1):115-126.
19. Marsac D., Loirat D., Petit C., Schwartz O., Michel M.L. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J Virol 2002, 76(15):7544-7553.
20. Di Bonito P., Grasso F., Mochi S., Petrone L., Fanales-Belasio E., Mei A., et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 2009, 395(1):45-55.
21. Kattenbeck B., von P.A., Rohrhofer A., Wolf H., Modrow S. Inhibition of human immunodeficiency virus type 1 particle formation by alterations of defined amino acids within the C terminus of the capsid protein. J Gen Virol 1997, 78(10):2489-2496.
22. Muller B., Daecke J., Fackler O.T., Dittmar M.T., Zentgraf H., Krausslich H.G. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004, 78(19):10803-10813.
23. Gorer P.A. Studies in antibody response of mice to tumour inoculation. Br J Cancer 1950, 4(4):372-379.
24. Accapezzato D., Visco V., Francavilla V., Molette C., Donato T., Paroli M., et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med 2005, 202(6):817-828.
25. Muratori C., D'Aloja P., Superti F., Tinari A., Sol-Foulon N., Sparacio S., et al. Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol 2006, 6:52.
26. Sparacio S., Pfeiffer T., Schaal H., Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001, 3(4):602-612.
27. Rotzschke O., Falk K., Deres K., Schild H., Norda M., Metzger J., et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990, 348(6298):252-254.
28. Bauer S., Heeg K., Wagner H., Lipford G.B. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand J Immunol 1995, 42(3):317-323.
29. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999, 6(3):165-181.
30. Kwong A.D., Kim J.L., Lin C. Structure and function of hepatitis C virus NS3 helicase. Curr Top Microbiol Immunol 2000, 242:171-196.
31. Muratori C., Bona R., Ruggiero E., D'Ettorre G., Vullo V., Andreotti M., et al. DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. Eur J Immunol 2009, 39(2):404-416.
32. Fredericksen B.L., Whitt M.A. Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J Virol 1995, 69(3):1435-1443.
33. Foster J.L., Garcia J.V. HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84.
34. Olivetta E., Pugliese K., Bona R., D'Aloja P., Ferrantelli F., Santarcangelo A.C., et al. cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails. J Virol 2000, 74(1):483-492.
35. D'Aloja P., Santarcangelo A.C., Arold S., Baur A., Federico M. Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele. J Gen Virol 2001, 82(Pt 11):2735-2745.
36. Fackler O.T., D'Aloja P., Baur A.S., Federico M., Peterlin B.M. Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity. J Virol 2001, 75(14):6601-6608.
37. Green L.A., Liu Y., He J.J. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. J Biol Chem 2009, 284(20):13363-13372.
38. Saksela K., Cheng G., Baltimore D. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 1995, 14(3):484-491.
39. Blagoveshchenskaya A.D., Thomas L., Feliciangeli S.F., Hung C.H., Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002, 111(6):853-866.
40. Trible R.P., Emert-Sedlak L., Smithgall T.E. HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem 2006, 281(37):27029-27038.
41. Napolitani G., Bortoletto N., Racioppi L., Lanzavecchia A., D'Oro U. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol 2003, 33(10):2832-2841.
42. Chu C.L., Lowell C.A. The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol 2005, 175(5):2880-2889.
43. Wagner R., Deml L., Fliessbach H., Wanner G., Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 1994, 200(1):162-175.
44. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000, 16(3):273-282.
45. Young K.R., Ross T.M. Elicitation of immunity to HIV type 1 Gag is determined by Gag structure. AIDS Res Hum Retroviruses 2006, 22(1):99-108.
46. Buonaguro L., Tornesello M.L., Tagliamonte M., Gallo R.C., Wang L.X., Kamin-Lewis R., et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006, 80(18):9134-9143.
47. Luo L., Li Y., Ha S.D., Kang C.Y. Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles. Virus Genes 2007, 35(2):187-193.
48. Blackard J.T., Shata M.T., Shire N.J., Sherman K.E. Acute hepatitis C virus infection: a chronic problem. Hepatology 2008, 47(1):321-331.
49. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10(4):439-449.
50. He X.S., Rehermann B., Lopez-Labrador F.X., Boisvert J., Cheung R., Mumm J., et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999, 96(10):5692-5697.
51. Klenerman P., Lucas M., Barnes E., Harcourt G. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect 2002, 4(1):57-65.
52. Verhasselt B., Naessens E., Verhofstede C., De S.M., Schollen S., Kerre T., et al. Human immunodeficiency virus nef gene expression affects generation and function of human T cells, but not dendritic cells. Blood 1999, 94(8):2809-2818.
53. Cramer L.A., Frelinger J.A. Dendritic cells transduced with HIV Nef express normal levels of HLA-A and HLA-B class I molecules. J Acquir Immune Defic Syndr 2001, 27(5):417-425.
54. Maccormac L.P., Jacque J.M., Chain B. The functional consequences of delivery of HIV-1 Nef to dendritic cells using an adenoviral vector. Vaccine 2004, 22(3-4):528-535.
55. Yamamoto T., Isogai M., Otake K., Tsunetsugu-Yokota Y. High and inducible expression of human immunodeficiency virus type 1 (HIV-1) Nef by adenovirus vector does not disturb potent antigen presentation by monocyte-derived dendritic cells. Microbes Infect 2006, 8(9-10):2522-2530.
56. Wolf D., Witte V., Clark P., Blume K., Lichtenheld M.G., Baur A.S. HIV Nef enhances Tat-mediated viral transcription through a hnRNP-K-nucleated signaling complex. Cell Host Microbe 2008, 4(4):398-408.
57. Wolf D., Giese S.I., Witte V., Krautkramer E., Trapp S., Sass G., et al. Novel (n)PKC kinases phosphorylate Nef for increased HIV transcription, replication and perinuclear targeting. Virology 2008, 370(1):45-54.
58. Olivetta E., Percario Z., Fiorucci G., Mattia G., Schiavoni I., Dennis C., et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol 2003, 170(4):1716-1727.
59. Percario Z., Olivetta E., Fiorucci G., Mangino G., Peretti S., Romeo G., et al. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J Leukoc Biol 2003, 74(5):821-822.